Mycobacterium abscessus and kansasii successfully treated with inhaled amikacin: Case report

Introduction: Pulmonary infections by nontuberculous mycobacteria (NTM) represent a serious clinical problem because they produce progressive, severe and difficult to treat pictures. Case report: We present two patients without immunosuppressive comorbidity with pulmonary infection by Mycobacterium...

ver descrição completa

Detalhes bibliográficos
Autores: Ramirez, Percy C., Campos-Huaman, Alex, Segama-Gonzales, Jossmert, Montalvo-Otivo , Raúl
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:Perú
Recursos:Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Repositorio:Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo
Idioma:español
OAI Identifier:oai:cmhnaaa_ojs_cmhnaaa.cmhnaaa.org.pe:article/2357
Acesso em linha:https://cmhnaaa.org.pe/ojs/index.php/rcmhnaaa/article/view/2357
Access Level:acceso abierto
Palavra-chave:Mycobacterium
Micobacterias no Tuberculosas
Mycobacterium abscessus
Mycobacterium kansasii
Amicacina
Nontuberculous Mycobacteria
Amikacin
Descrição
Resumo:Introduction: Pulmonary infections by nontuberculous mycobacteria (NTM) represent a serious clinical problem because they produce progressive, severe and difficult to treat pictures. Case report: We present two patients without immunosuppressive comorbidity with pulmonary infection by Mycobacterium abscessus and Mycobacterium kansasii, with clinical and radiographic improvement after receiving inhalation amikacin. The use of this drug added to standard therapy allowed a favorable evolution due to its high concentration in the alveolar tissue in infection by non-tuberculous mycobacteria. Discussion: Initial therapy to treat NTM infections based on a macrolide, ethambutol and rifampicin is often not sufficient. Inhalation amikacin is proposed as rescue therapy due to its potent antimicrobial activity, achieving a high concentration and a longer time in lung tissue with less toxic effects. Conclusion: A favorable clinical response was evidenced with the combined treatment with inhaled amikacin.